Johnson & Johnson Hunts Dengue Fever Drug and 2 Other Dow Movers to Watch

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Johnson & Johnson (NYSE:JNJ): Current price $86.86

The iconic U.S. company is searching for drugs with which to treat dengue fever by partnering with academic researchers in Belgium and the Wellcome Trust medical charity. Presently, there exists no drug treatment or vaccine for the mosquito-borne viral disease, which is also known as “breakbone fever” due to the excruciating pain it can cause.

The collaboration between J&J’s Janssen division and researchers at the University of Leuven, who get support from Wellcome, will build on the discovery of a series of chemical compounds which are quite potent in preventing the replication of dengue virus.

jnj-20130829

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business